Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + fulvestrant vs placebo + fulvestrant in HR+/HER2- advanced breast cancer after aromatase inhibitor
jRCT2080225182Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Capivasertib + fulvestrant with Placebo + fulvestrant (2 arms). Started Apr 2020; status: completed.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080225182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225182.